Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 2
1991 1
1992 1
1994 1
1995 1
1996 1
1997 1
1999 1
2006 2
2007 6
2010 1
2011 1
2012 3
2016 3
2017 2
2018 1
2020 1
2021 1
2022 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
Crawford J, Calle RA, Collins SM, Weng Y, Lubaczewski SL, Buckeridge C, Wang EQ, Harrington MA, Tarachandani A, Rossulek MI, Revkin JH. Crawford J, et al. Among authors: revkin jh. Clin Cancer Res. 2024 Feb 1;30(3):489-497. doi: 10.1158/1078-0432.CCR-23-1631. Clin Cancer Res. 2024. PMID: 37982848 Free PMC article. Clinical Trial.
Surrogate endpoints in randomized cardiovascular clinical trials.
Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Domanski M, et al. Among authors: revkin j. Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Fundam Clin Pharmacol. 2011. PMID: 20698890 Review.
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week.
Van Spall HGC, Lala A, Deering TF, Casadei B, Zannad F, Kaul P, Mehran R, Pearson GD, Shah MR, Gulati M, Grines C, Volgman AS, Revkin JH, Piña I, Lam CSP, Hochman JS, Simon T, Walsh MN, Bozkurt B; Global CardioVascular Clinical Trialists (CVCT) Forum and Women As One Scientific Expert Panel. Van Spall HGC, et al. Among authors: revkin jh. J Am Coll Cardiol. 2021 Jun 15;77(23):2960-2972. doi: 10.1016/j.jacc.2021.04.038. J Am Coll Cardiol. 2021. PMID: 34112322 Free article. Review.
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank.
Seltzer JH, Farrell A, Goldenberg N, Hornik C, Keene D, Krucoff MW, Lipardi C, Massicotte P, Mentzer D, Monagle P, Thornburg C, Revkin JH, Walker S, Gajjar D. Seltzer JH, et al. Among authors: revkin jh. Am Heart J. 2020 Jun;224:138-147. doi: 10.1016/j.ahj.2020.02.012. Epub 2020 Feb 28. Am Heart J. 2020. PMID: 32388153 Free article. Review. No abstract available.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Ridker PM, et al. Among authors: revkin j. N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304227 Free article. Clinical Trial.
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Anker SD, et al. Among authors: revkin j. Eur J Heart Fail. 2016 May;18(5):482-9. doi: 10.1002/ejhf.516. Epub 2016 Apr 12. Eur J Heart Fail. 2016. PMID: 27071916 Free article. Review.
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, Reiner Z, Koenig W, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Zannad F, et al. Fundam Clin Pharmacol. 2012 Apr;26(2):163-74. doi: 10.1111/j.1472-8206.2011.01023.x. Epub 2012 Jan 5. Fundam Clin Pharmacol. 2012. PMID: 22220636 Review.
34 results